HR leaders should be prepared to address employee questions, evaluate plan coverage, communicate clearly about eligibility and costs, and consider supportive wellness strategies such as nutrition counselng, physical activity programs, and chronic disease prevention resources
Sources: FDA Drug Safety Communication, Jan 13, 2026 FDA prescribing labels: Ozempic, Wegovy, Mounjaro, Zepbound EMA / PRAC statement on NAION, June 6, 2025 UK MHRA Drug Safety Update on semaglutide & NAION Endocrine Society of India Clinical Practice Guidelines for Obesity, 2025 Disclaimer: This content is for educational purposes only and is not medical advice, diagnosis, or treatment
The amount of weight loss you may go through while taking Semaglutide GLP-1 can depend on various factors such as your individual metabolism, diet, exercise habits, and other health conditions
Moreover, mortality alone is an insufficient means to measure the impact of CAD, as it is also the leading global cause of cardiovascular morbidity, imposing over 200 million disability-adjusted life years on patients living with the sequelae of ischemic cardiomyopathy
Retatrutide Is a First-in-Its-Class Medication Retatrutide is a triple agonist medication, meaning it works on three different hormone receptors in the body: GLP-1, GIP, and glucagon leading some experts to call it a triple-G drug
These numbers exceed every other obesity medication currently available or in development
